FDAnews
www.fdanews.com/articles/208048-viiv-to-license-its-hiv-prevention-drug-to-mpp

ViiV to License Its HIV Prevention Drug to MPP

June 1, 2022

ViiV Healthcare has agreed to license patents covering Apretude (cabotegravir), its long-acting human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) drug, to the Medicines Patent Pool (MPP) to increase access to medicines in low- and middle-income countries.

The United Nations-backed MPP said it will now negotiate with ViiV to secure a license to enable the development of generic versions of Apretude.  MPP believes Apretude could potentially be “a very important drug” in the battle against HIV because of its long-acting nature.

The company said that until a generic version of the drug is available, ViiV will supply Apretude to public programs in “low-income, least-developed and all sub-Saharan African countries” at what it calls a “nonprofit price.” Apretude, which was FDA-approved in December 2021, costs $3,700 per dose.

View today's stories